Skip to main content
. 2020 Feb 26;8(2):e16266. doi: 10.2196/16266

Table 3.

Adverse events through 3 months.

Adverse events Control group (n=94), n (%) Intervention group (n=145), n (%) P value
Any adverse events 8 (9) 18 (12.4) .35

Elevated liver enzymes 5 (5) 12 (8.3)

Renal impairment 2 (2) 1 (0.7)

Mild hypoglycemia 0 (0) 5 (3.5)

Serious adverse events




Death 1 (1)a 0 (0)

aDeath from cerebral infarction.